May 16, 2023 / 01:30PM GMT
Brian Corey Abrahams - RBC Capital Markets, Research Division - Senior Biotechnology Analyst
Again for being here. I'm Brian Abrahams, 1 of the senior biotech analysts here at RBC Capital Markets. Our next feature company is Regeneron. And since I picked up coverage of the company, I'd be getting more and more questions about what's going on in Regeneron's pipeline? Of course, I get a lot of questions on EYLEA and Dupixent. But people I think are more and more interested in learning about the R&D engine.
And so we're really pleased to feature today, I think, a different aspect of Regeneron than many people get a chance to see and understand. We have with us Aris Baras, who's the Senior Vice President of the Regeneron's -- Regeneron Genetics Center, as well as Christos Kyratsous, the Senior Vice President of Research; and Ryan Crowe here on stage as well, who's their Vice President of Investor Relations. And they're going to walk us through a little bit more about what goes on behind the scenes at Regeneron that enables them to maintain 1 of the broadest pipelines in all of biotech. So thank
Regeneron Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 16, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers